Flow Pharma, Inc.
Flow Pharma Inc. is dedicated to immunotherapy innovation, focusing on developing vaccines and therapies for viral diseases and cancers. Their mission is to transform the treatment and prevention of cancer and viral diseases through their exclusive technology and manufacturing expertise, utilizing artificial intelligence, bioinformatics, synthetic biochemistry, and advanced vaccine platforms such as peptide-based and microsphere delivery systems. They are actively engaged in research targeting internal viral proteins like nucleocapsid to develop broad-spectrum and mutation-resistant vaccines, including for COVID-19, Ebola, Marburg, and Zika viruses. Their approach emphasizes T-cell mediated immunity, aiming to produce effective, room-temperature stable vaccines that can be delivered via inhalation or injection, with broad HLA coverage for global populations.
Industries
Nr. of Employees
small (1-50)
Flow Pharma, Inc.
Cleveland, Ohio, United States, North America
Products
Room-temperature-stable peptide vaccine candidate targeting conserved viral nucleocapsid epitopes (development-stage)
Preclinical-stage peptide vaccine formulation targeting conserved nucleocapsid-derived epitopes intended for pulmonary or parenteral administration to stimulate T-cell immunity against coronaviruses; undergoing preclinical evaluation and clinical manufacturing readiness activities.
Microsphere-based CTL vaccine candidates for filoviruses (development-stage)
Peptide vaccine constructs based on conserved nucleocapsid epitopes for prophylaxis against filoviruses, formulated as adjuvanted polymer microspheres and progressing through preclinical testing.
Neoantigen-targeted peptide immunotherapy candidates for oncology (development-stage)
Therapeutic peptide vaccine approaches that use sequencing and computational neoantigen identification to select tumor-specific peptides for intranodal or intramuscular administration, aimed at treatment-resistant cancers including triple-negative breast cancer and virus-associated malignancies.
Room-temperature-stable peptide vaccine candidate targeting conserved viral nucleocapsid epitopes (development-stage)
Preclinical-stage peptide vaccine formulation targeting conserved nucleocapsid-derived epitopes intended for pulmonary or parenteral administration to stimulate T-cell immunity against coronaviruses; undergoing preclinical evaluation and clinical manufacturing readiness activities.
Microsphere-based CTL vaccine candidates for filoviruses (development-stage)
Peptide vaccine constructs based on conserved nucleocapsid epitopes for prophylaxis against filoviruses, formulated as adjuvanted polymer microspheres and progressing through preclinical testing.
Neoantigen-targeted peptide immunotherapy candidates for oncology (development-stage)
Therapeutic peptide vaccine approaches that use sequencing and computational neoantigen identification to select tumor-specific peptides for intranodal or intramuscular administration, aimed at treatment-resistant cancers including triple-negative breast cancer and virus-associated malignancies.
Services
Preclinical vaccine development and challenge testing
Design and execution of preclinical efficacy, challenge and immunogenicity studies in murine and non-human primate models, including collaboration with high-containment laboratories, viral challenge protocols, immunoassay readouts, bronchoalveolar lavage sampling and gene-expression profiling.
Bioinformatics, epitope identification and genomic surveillance
Remote and collaborative bioinformatics workflows to predict MHC-binding peptides, identify neoantigen and conserved epitope targets, model HLA population coverage, and perform large-scale sequence curation, variant frequency analysis and phylogenetic inference for infectious disease and oncology programs.
Microsphere formulation and GMP manufacturing partnerships
Development and scale-up of PLGA microsphere-based formulations and coordination with GMP manufacturing partners for clinical batch production, stability testing and room-temperature-stable dry powder product pathways.
Regulatory and clinical program support
Consulting and program management to prepare peptide-based vaccine candidates for clinical testing, including protocol planning, clinical manufacturing coordination, regulatory engagement and operational readiness for early-phase studies.
Computational pocket identification and small-molecule pharmacophore modeling
In silico identification of ligandable pockets on pathogen and host proteins and generation of pharmacophore models to guide small-molecule design to stabilize protein conformations or inhibit functional sites.
Preclinical vaccine development and challenge testing
Design and execution of preclinical efficacy, challenge and immunogenicity studies in murine and non-human primate models, including collaboration with high-containment laboratories, viral challenge protocols, immunoassay readouts, bronchoalveolar lavage sampling and gene-expression profiling.
Bioinformatics, epitope identification and genomic surveillance
Remote and collaborative bioinformatics workflows to predict MHC-binding peptides, identify neoantigen and conserved epitope targets, model HLA population coverage, and perform large-scale sequence curation, variant frequency analysis and phylogenetic inference for infectious disease and oncology programs.
Microsphere formulation and GMP manufacturing partnerships
Development and scale-up of PLGA microsphere-based formulations and coordination with GMP manufacturing partners for clinical batch production, stability testing and room-temperature-stable dry powder product pathways.
Regulatory and clinical program support
Consulting and program management to prepare peptide-based vaccine candidates for clinical testing, including protocol planning, clinical manufacturing coordination, regulatory engagement and operational readiness for early-phase studies.
Computational pocket identification and small-molecule pharmacophore modeling
In silico identification of ligandable pockets on pathogen and host proteins and generation of pharmacophore models to guide small-molecule design to stabilize protein conformations or inhibit functional sites.
Expertise Areas
- Peptide-based cytotoxic T-lymphocyte (CTL) vaccine design
- Large-scale viral sequence curation and genomic surveillance
- MHC class I and II binding prediction and HLA population-coverage optimization
- Structure-based epitope constraint and variant-effect prediction
Key Technologies
- MHC-binding prediction algorithms (neural-network and pan-specific models)
- Sequence alignment and consensus-sequence generation (MAFFT/webPRANK-style workflows)
- HLA population-coverage and epitope set optimization
- Molecular modeling with residue-scan free-energy calculations and structural-entropy metrics